For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.
Getting Started is Easy and Yes It's FREE
What is The Ecosystem?
The Token Revolution.
The Next Bitcoin Moment.
